Instruction for use: Piportil L4

Dosage form: solution for injections

Active substance: Pipotiazine*

ATX

N05AC04 Pipotiazine

Pharmacological group:

Neuroleptics

The nosological classification (ICD-10)

F20 Schizophrenia: Schizophrenic conditions; Exacerbation of schizophrenia; Schizophrenia; Chronic schizophrenia; Dementia praecox; Bleuler's disease; Psychotic discordant; Dementia early; The febrile form of schizophrenia; Chronic schizophrenic disorder; Psychosis of the schizophrenic type; Acute form of schizophrenia; Acute schizophrenic disorder; Cerebral Organic Insufficiency in Schizophrenia; Acute attack of schizophrenia; Schizophrenic psychosis; Acute schizophrenia; Sluggish schizophrenia; Sluggish schizophrenia with apathoabulic disorders; Acute stage of schizophrenia with excitation

F22 Chronic Delusional Disorders: Delusional Chronic Disorder; Delusional Disorders; Delusional syndrome; Paranoia; Chronic affective-delirious states

F29 Inorganic psychosis, unspecified: Childhood psychoses; Psychomotor agitation in psychoses; Hallucinatory-delusional disorders; Hallucinatory-delusional syndrome; Intoxication psychosis; Manic-delusional disorders; Manic chronic psychosis; Manic psychosis; Acute psychosis; paranoid psychosis; Paranoid psychosis; Subacute psychosis; Presenile psychosis; Psychosis; Intoxication psychosis; Psychosis is paranoid; Psychosis in children; Reactive psychosis; Chronic psychosis; Chronic hallucinatory psychosis; Chronic psychosis; Chronic psychotic disorder; Schizophrenic psychosis

Composition and release form

An ampoule with 1 or 4 ml of a solution in oil for IM injections contains 25 mg or 100 mg of pipotiazine palmitate, respectively; in a carton box 3 or 1 ampoule, respectively.

Pharmachologic effect

Pharmacological action - antipsychotic, neuroleptic.

Brakes synaptic transmission in the brain.

Clinical Pharmacology

Has a general effect on a complex of psychotic processes - reduces psychotic symptoms, reduces psychotic fear, depersonalization, psychomotor agitation, aggressiveness, inconsistency, eliminates psychomotor inhibition. The active substance of the preparation is slowly released by hydrolysis of palmitate at the site of administration, which allows to refuse daily injections.

Indications for the drug Piportil L4

Chronic psychosis, delusional disorders, schizophrenia.

Contraindications

Toxic agranulocytosis in anamnesis, angle-closure glaucoma, porphyria, prostate diseases.

Application in pregnancy and lactation

With caution, since harmlessness is not established.

Side effects

Depression, dyskinesia: early (spasmodic torticollis, oculomotor crisis, trismus) and late, extrapyramidal disorders; Orthostatic hypotension, dry mouth, constipation, paresis of accommodation, in the treatment of epilepsy (due to the possible lowering of the epileptogenic threshold) and parkinsonism. Caution is necessary when prescribing in elderly patients (sedative and hypotensive effects); with cardiovascular diseases, renal or hepatic insufficiency; for drivers of transport and persons working with mechanisms (drowsiness and decreased reaction, especially at the beginning of treatment).

Conditions for storage of Piportil L4

In the dark place at a temperature of no higher than 25 ° C.

Keep out of the reach of children.

Shelf life of the drug Piportil L4

4 years.

Do not use after the expiry date printed on the package.